Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province
Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province
复制标题
DOI：
10.1080/00207454.2019.1694925
复制
发表时间：
2019-12-03
影响因子：
2.2
通讯作者：
Jahanbani-Ardakani, Hamidreza
中科院分区：
文献类型：
--
作者：
Jafarinia, Morteza;Sadeghi, Erfan;Jahanbani-Ardakani, Hamidreza
背景：多发性硬化症（MS）是一种中枢神经系统（CNS）的神经炎症性疾病。神经炎症可诱导促炎细胞因子如骨桥蛋白（OPN）。OPN通过调节T助剂1 （Th1）和Th17反应在炎症中起重要作用。由于MS的确切免疫发病机制复杂且不明确，而且涉及许多因素，因此检测更多有贡献的生物标志物可能有助于制定新的治疗策略。目的：本研究试图比较伊斯法罕省复发-缓解型多发性硬化症（RRMS）患者与健康受试者在缓解期的血浆OPN水平。材料和方法：在病例对照研究中，收集40例RRMS和38例（年龄和性别匹配）健康个体的血浆作为对照组。采用酶联免疫吸附法（ELISA）测定两组患者血浆opn水平并进行比较。结果：经统计学分析，病例组（缓解期RRMS患者）血浆OPN水平明显高于对照组（P值= 0.039）。我们的研究结果还显示，在接受干扰素(IFN)-ss治疗的RRMS患者中，血浆OPN水平的平均值与未接受干扰素-ss治疗的RRMS患者无统计学差异（P值= 0.332）。血浆OPN水平与EDSS评分（r = 0.037， P值= 0.835）、发病年龄（r = 0.161， P值= 0.357）、病程（r = 0.121， P值= 0.490）无相关性。结论：研究患者血浆中OPN水平升高，表明处于缓解期的RRMS患者的OPN水平升高。可以假设，血浆OPN水平的升高可能是MS患者中促炎细胞因子环境的一部分。OPN可能不是MS的特异性标志物，但靶向OPN可能对MS患者有很好的治疗效果。
Background: Multiple sclerosis (MS) is known as a neuroinflammatory disease of the central nervous system (CNS). The neuroinflammation may induce pro-inflammatory cytokines such as Osteopontin (OPN). OPN plays an important role in the inflammation by modulating the T helper1 (Th1) and Th17 responses. Since the exact immune pathogenesis of MS is complex and not well defined and many factors are involved, the need to detect more contributing biomarkers may help in setting new therapeutic strategies. Objective: This study tried to compare plasma OPN levels in relapsing- remitting multiple sclerosis (RRMS) patients during the remission phase with healthy subjects in Isfahan province. Materials and methods: In a case-control study, plasma was collected from the 40 RRMS as well as 38 (age and sex matched) healthy individuals as a control group. PlasmaOPN level was measured and compared between the two groups by Enzyme-linked immunosorbent assays (ELISA). Result: Statistical analysis revealed that plasma OPN level was markedly higher in the case group (RRMS patients during the remission phase) compared with the control group (P- value = 0.039). Our results also showed that there was no statistically significant difference in mean of plasma OPN level among RRMS patients who were treated with interferon (IFN)-ss and those who were not (P- value = 0.332). There was also no correlation between OPN plasma level and EDSS score (r = 0.037, P- value = 0.835), age of onset (r = 0.161, P- value = 0.357) and duration of disease (r = 0.121, P- value = 0.490). Conclusion: Higher OPN plasma level in studied patients suggests that OPN increased in RRMS patients who were in remission phase. It could be hypothesized that plasma OPN level may be increased as part of the pro-inflammatory cytokine milieu taking place in MS patients. OPN may not be specific marker for MS, but targeting it might present promising therapeutic effect to MS patients.